The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

被引:1312
作者
Cohn, Susan L. [1 ]
Pearson, Andrew D. J.
London, Wendy B.
Monclair, Tom
Ambros, Peter F.
Brodeur, Garrett M.
Faldum, Andreas
Hero, Barbara
Iehara, Tomoko
Machin, David
Mosseri, Veronique
Simon, Thorsten
Garaventa, Alberto
Castel, Victoria
Matthay, Katherine K.
机构
[1] Univ Chicago, Sect Pediat Hematol Oncol, Dept Pediat, Chicago, IL 60637 USA
关键词
PEDIATRIC-ONCOLOGY-GROUP; LOCALIZED NEUROBLASTOMA; FAVORABLE PROGNOSIS; NEURO-BLASTOMA; SURVIVAL TREES; CHROMOSOME; 1P; CRITERIA; AGE; AMPLIFICATION; PROGRESSION;
D O I
10.1200/JCO.2008.16.6785
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Because current approaches to risk classification and treatment stratification for children with neuroblastoma (NB) vary greatly throughout the world, it is difficult to directly compare risk-based clinical trials. The International Neuroblastoma Risk Group (INRG) classification system was developed to establish a consensus approach for pretreatment risk stratification. Patients and Methods The statistical and clinical significance of 13 potential prognostic factors were analyzed in a cohort of 8,800 children diagnosed with NB between 1990 and 2002 from North America and Australia (Children's Oncology Group), Europe (International Society of Pediatric Oncology Europe Neuroblastoma Group and German Pediatric Oncology and Hematology Group), and Japan. Survival tree regression analyses using event-free survival (EFS) as the primary end point were performed to test the prognostic significance of the 13 factors. Results Stage, age, histologic category, grade of tumor differentiation, the status of the MYCN oncogene, chromosome 11q status, and DNA ploidy were the most highly statistically significant and clinically relevant factors. A new staging system (INRG Staging System) based on clinical criteria and tumor imaging was developed for the INRG Classification System. The optimal age cutoff was determined to be between 15 and 19 months, and 18 months was selected for the classification system. Sixteen pretreatment groups were defined on the basis of clinical criteria and statistically significantly different EFS of the cohort stratified by the INRG criteria. Patients with 5-year EFS more than 85%, more than 75% to <= 85%, >= 50% to <= 75%, or less than 50% were classified as very low risk, low risk, intermediate risk, or high risk, respectively. Conclusion By defining homogenous pretreatment patient cohorts, the INRG classification system will greatly facilitate the comparison of risk-based clinical trials conducted in different regions of the world and the development of international collaborative studies.
引用
收藏
页码:289 / 297
页数:9
相关论文
共 32 条
  • [1] Chromosome 1p and 11q deletions and outcome in neuroblastoma
    Attiyeh, EF
    London, WB
    Mossé, YP
    Wang, Q
    Winter, C
    Khazi, D
    McGrady, PW
    Seeger, RC
    Look, AT
    Shimada, H
    Brodeur, GM
    Cohn, SL
    Matthay, KK
    Maris, JM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21) : 2243 - 2253
  • [2] Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma
    Bown, N
    Cotterill, S
    Lastowska, M
    O'Neill, S
    Pearson, ADJ
    Plantaz, D
    Meddeb, M
    Danglot, G
    Brinkschmidt, C
    Christiansen, H
    Laureys, G
    Speleman, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (25) : 1954 - 1961
  • [3] REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT
    BRODEUR, GM
    PRITCHARD, J
    BERTHOLD, F
    CARLSEN, NLT
    CASTEL, V
    CASTLEBERRY, RP
    DEBERNARDI, B
    EVANS, AE
    FAVROT, M
    HEDBORG, F
    KANEKO, M
    KEMSHEAD, J
    LAMPERT, F
    LEE, REJ
    LOOK, AT
    PEARSON, ADJ
    PHILIP, T
    ROALD, B
    SAWADA, T
    SEEGER, RC
    TSUCHIDA, Y
    VOUTE, PA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) : 1466 - 1477
  • [4] INTERNATIONAL CRITERIA FOR DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT IN PATIENTS WITH NEURO-BLASTOMA
    BRODEUR, GM
    SEEGER, RC
    BARRETT, A
    BERTHOLD, F
    CASTLEBERRY, RP
    DANGIO, G
    DEBERNARDI, B
    EVANS, AE
    FAVROT, M
    FREEMAN, AI
    HAASE, G
    HARTMANN, O
    HAYES, FA
    HELSON, L
    KEMSHEAD, J
    LAMPERT, F
    NINANE, J
    OHKAWA, H
    PHILIP, T
    PINKERTON, CR
    PRITCHARD, J
    SAWADA, T
    SIEGEL, S
    SMITH, EI
    TSUCHIDA, Y
    VOUTE, PA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) : 1874 - 1881
  • [5] Neuroblastoma: Biological insights into a clinical enigma
    Brodeur, GM
    [J]. NATURE REVIEWS CANCER, 2003, 3 (03) : 203 - 216
  • [6] Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma
    Caron, H
    vanSluis, P
    deKraker, J
    Bokkerink, J
    Egeler, M
    Laureys, G
    Slater, R
    Westerveld, A
    Voute, PA
    Versteeg, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (04) : 225 - 230
  • [7] THE PEDIATRIC-ONCOLOGY-GROUP EXPERIENCE WITH THE INTERNATIONAL STAGING SYSTEM CRITERIA FOR NEUROBLASTOMA
    CASTLEBERRY, RP
    SHUSTER, JJ
    SMITH, EI
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) : 2378 - 2381
  • [8] Surgical risk factors in primary surgery for localized neuroblastoma:: The LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group
    Cecchetto, G
    Mosseri, V
    De Bernardi, B
    Helardot, P
    Monclair, T
    Costa, E
    Horcher, E
    Neuenschwander, S
    Tomà, P
    Rizzo, A
    Michon, J
    Holmes, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) : 8483 - 8489
  • [9] COX DR, 1972, J R STAT SOC B, V34, P187
  • [10] EXPONENTIAL SURVIVAL TREES
    DAVIS, RB
    ANDERSON, JR
    [J]. STATISTICS IN MEDICINE, 1989, 8 (08) : 947 - 961